The 40 million euro European project eTRANSAFE, kicked off at the end of September 2017, is aimed at speeding up the development of better and safer medicines for patients. Coordinated by the Fundació Institut Mar d'Investigacions Mèdiques and led by the pharmaceutical company Novartis, the project consortium is a public-private partnership of eight academic institutions, six SMEs, and twelve pharmaceutical companies. Fraunhofer ITEM’s assignment in the project is to evaluate whether and to what extent toxicological findings from preclinical data can be used to predict clinical findings. For this purpose, toxicologists and physicians will first analyze in detail the available preclinical data from existing databases such as eToxSys. The aim is to gather insights, for example, into the time dependence of toxicological effects or possibilities of substance grouping. In the next stage, the predictivity of preclinical data for human clinical effects will be analyzed.